Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance - Scorecard - MDSpire
Advertisement
Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance
Clinical Scorecard: Association of Soluble fms-like Tyrosine Kinase-1 with Peripartum Cardiomyopathy: An Exploratory Meta-Analysis of Diagnostic Efficacy
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Pregnant and postpartum women, particularly those with pre-eclampsia.
Care Setting
Key Highlights
additional_info
Guideline-Based Recommendations
Diagnosis
Management
Monitor patients with elevated sFlt-1 levels for PPCM development.
Further research needed to establish treatment protocols based on sFlt-1 levels.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Further research needed to establish treatment protocols based on sFlt-1 levels, including potential pharmacological options.
Clinical Best Practices
Utilize sFlt-1 as a potential biomarker for PPCM risk assessment.
Incorporate patient history of pre-eclampsia in risk stratification.
Conduct larger prospective studies to validate findings.
Encourage multidisciplinary collaboration in managing PPCM.
